Cargando…
P1031: LOW-DOSE DOACS IN VERY HIGH-RISK MYELOPROLIFERATIVE NEOPLASMS: LESS BLEEDING BUT MORE ARTERIAL THROMBOTIC EVENTS
Autores principales: | Herbreteau, L., Papageorgiou, L., Le Clech, L., Garcia, G., James, C., Pan-Petesch, B., Couturaud, F., Lippert, E., Gerotziafas, G., Ianotto, J.-C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430522/ http://dx.doi.org/10.1097/01.HS9.0000846992.75907.c1 |
Ejemplares similares
-
Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative
Neoplasms
por: Papageorgiou, Loula, et al.
Publicado: (2022) -
Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms
por: Orliaguet, Marie, et al.
Publicado: (2020) -
Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms
por: Vianello, Fabrizio, et al.
Publicado: (2011) -
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
por: Huenerbein, Karlo, et al.
Publicado: (2020) -
Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology
por: Chia, Yuh Cai, et al.
Publicado: (2023)